Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729438 | 0.89 | GPR55 (0.55) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL22729541 | 0.85 | USP2 (0.64) | KMT2AUSP2RXFP1NPC1RAB9A | |
| SCHEMBL22729676 | 0.83 | TDP1 (0.53) | MEN1KMT2ARXFP1LMNATP53 | |
| SCHEMBL22729472 | 0.82 | RAB9A (0.55) | MEN1KMT2AUSP2NPC1RAB9A | |
| SCHEMBL22729593 | 0.80 | PNLIP (0.49) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL11779160 | 0.78 | KMT2A (0.63) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL22755173 | 0.76 | GPR55 (0.53) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL22729486 | 0.75 | BRD4 (0.65) | MEN1KMT2ANPC1RAB9ATP53 | |
| SCHEMBL22647160 | 0.75 | MEN1 (0.55) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL22729677 | 0.74 | MAPT (0.53) | MEN1KMT2ARXFP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | PDK1 2009/4885PDK2 1583/4885PDK3 2192/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | PDK1 1930/4885PDK2 1505/4885PDK3 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.